Gilead Sciences is letting go of 114 employees based out of the company’s Morris Plains, New Jersey facility following an underwhelming response to the results reaped so far from the $21 billion acquisition of Immunomedics in 2020, according to BioSpace.
Illumina Inc. faces yet another setback from regulatory officials regarding the company’s $8 billion acquisition of GRAIL Inc. as the European Commission provided an update.
Biocon Biologics acquired partner Viatris’ biosimilars assets in a transaction that is part of an effort to create a global, vertically integrated biosimilars leader.
Biohaven, a clinical-stage biopharmaceutical company that innovates late-stage products for neurological and neuropsychiatric diseases, announced two major growth achievements.
BioDelivery Sciences International Inc. entered into a definitive merger agreement for Collegium Pharmaceutical Inc. to purchase all outstanding shares of BDSI at $5.60 per share in an all-cash transaction.
The U.S. health regulator approved the first generic version of AbbVie Inc.’s Restasis, a treatment used in increasing tear production in patients with dry-eye syndrome.
AbbVie reported the company’s fourth-quarter 2021 and full-year financial results on Feb. 2, with worldwide net reviews up 7.4% to $14.89 billion for the quarter. Total revenues for 2021 were $56 billion. The company’s anchor product remains Humira, which will begin to lose exclusivity in 2023.
Belgium’s UCB is acquiring California-based Zogenix, a company focused on rare diseases, in a deal valued up to €1.7 billion ($1.9 billion).
After a rejection from GlaxoSmithKline on a proposed £50 billion (about $68 billion) buyout of GSK’s consumer healthcare business, Unilever announced that the global consumer product giant will not increase its bid.
GlaxoSmithKline declined all three of Unilever’s offers to acquire GSK’s consumer healthcare business, saying the proposal undervalued the division’s present and further worth.
